Simone Jacobs1, Janine Kröger1, Anna Floegel1, Heiner Boeing1, Dagmar Drogan1, Tobias Pischon1, Andreas Fritsche1, Cornelia Prehn1, Jerzy Adamski1, Berend Isermann1, Cornelia Weikert1, Matthias B Schulze1. 1. From the Departments of Molecular Epidemiology (SJ, JK, and MBS) and Epidemiology (A Floegel, HB, CW, and DD), German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany (CP and JA); Molecular Epidemiology Group, Max Delbrueck Center for Molecular Medicine Berlin-Buch, Berlin, Germany (TP); the Department of Internal Medicine, Division of Endocrinology, Diabetology, Nephrology, Vascular Disease, and Clinical Chemistry, University Hospital of the Eberhard Karls University, Tübingen, Germany (A Fritsche); Institute for Diabetes Research and Metabolic Diseases of the Helmholz Centre Munich at the University of Tübingen (IDM), Tübingen, Germany (A Fritsche); the Department for Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany (BI); and the German Center for Diabetes Research (DZD), Neuherberg, Germany (SJ, A Fritsche, JK, and MBS).
Abstract
BACKGROUND: The inverse association between coffee consumption and the risk of type 2 diabetes (T2D) is well established; however, little is known about potential mediators of this association. OBJECTIVE: We aimed to investigate the association between coffee consumption and diabetes-related biomarkers and their potential role as mediators of the association between coffee consumption and T2D. DESIGN: We analyzed a case-cohort study (subcohort: n = 1610; verified incident T2D cases: n = 417) nested within the European Prospective Investigation into Cancer and Nutrition-Potsdam study involving 27,548 middle-aged participants. Habitual coffee consumption was assessed with a validated, semiquantitative food-frequency questionnaire. We evaluated the association between coffee consumption and several T2D-related biomarkers, such as liver markers (reflected by γ-glutamyltransferase, fetuin-A, and sex hormone-binding globulin), markers of dyslipidemia (high-density lipoprotein cholesterol and triglycerides), inflammation [C-reactive protein (CRP)], an adipokine (adiponectin), and metabolites, stratified by sex. RESULTS: Coffee consumption was inversely associated with diacyl-phosphatidylcholine C32:1 in both sexes and with phenylalanine in men, as well as positively associated with acyl-alkyl-phosphatidylcholines C34:3, C40:6, and C42:5 in women. Furthermore, coffee consumption was inversely associated with fetuin-A (P-trend = 0.06) and CRP in women and γ-glutamyltransferase and triglycerides in men. Coffee consumption tended to be inversely associated with T2D risk in both sexes, reaching significance only in men [HR (95% CI): women: ≥4 compared with >0 to <2 cups coffee/d: 0.78 (0.46, 1.33); men: ≥5 compared with >0 to <2 cups coffee/d: 0.40 (0.19, 0.81)]. The association between coffee consumption and T2D risk in men was slightly reduced after adjustment for phenylalanine or lipid markers. CONCLUSIONS: Coffee consumption was inversely associated with a diacyl-phosphatidylcholine and liver markers in both sexes and positively associated with certain acyl-alkyl-phosphatidylcholines in women. Furthermore, coffee consumption showed an inverse trend with CRP in women and with triglycerides and phenylalanine in men. However, these markers explained only to a small extent the inverse association between long-term coffee consumption and T2D risk.
BACKGROUND: The inverse association between coffee consumption and the risk of type 2 diabetes (T2D) is well established; however, little is known about potential mediators of this association. OBJECTIVE: We aimed to investigate the association between coffee consumption and diabetes-related biomarkers and their potential role as mediators of the association between coffee consumption and T2D. DESIGN: We analyzed a case-cohort study (subcohort: n = 1610; verified incident T2D cases: n = 417) nested within the European Prospective Investigation into Cancer and Nutrition-Potsdam study involving 27,548 middle-aged participants. Habitual coffee consumption was assessed with a validated, semiquantitative food-frequency questionnaire. We evaluated the association between coffee consumption and several T2D-related biomarkers, such as liver markers (reflected by γ-glutamyltransferase, fetuin-A, and sex hormone-binding globulin), markers of dyslipidemia (high-density lipoprotein cholesterol and triglycerides), inflammation [C-reactive protein (CRP)], an adipokine (adiponectin), and metabolites, stratified by sex. RESULTS: Coffee consumption was inversely associated with diacyl-phosphatidylcholine C32:1 in both sexes and with phenylalanine in men, as well as positively associated with acyl-alkyl-phosphatidylcholines C34:3, C40:6, and C42:5 in women. Furthermore, coffee consumption was inversely associated with fetuin-A (P-trend = 0.06) and CRP in women and γ-glutamyltransferase and triglycerides in men. Coffee consumption tended to be inversely associated with T2D risk in both sexes, reaching significance only in men [HR (95% CI): women: ≥4 compared with >0 to <2 cups coffee/d: 0.78 (0.46, 1.33); men: ≥5 compared with >0 to <2 cups coffee/d: 0.40 (0.19, 0.81)]. The association between coffee consumption and T2D risk in men was slightly reduced after adjustment for phenylalanine or lipid markers. CONCLUSIONS: Coffee consumption was inversely associated with a diacyl-phosphatidylcholine and liver markers in both sexes and positively associated with certain acyl-alkyl-phosphatidylcholines in women. Furthermore, coffee consumption showed an inverse trend with CRP in women and with triglycerides and phenylalanine in men. However, these markers explained only to a small extent the inverse association between long-term coffee consumption and T2D risk.
Authors: Erikka Loftfield; Meredith S Shiels; Barry I Graubard; Hormuzd A Katki; Anil K Chaturvedi; Britton Trabert; Ligia A Pinto; Troy J Kemp; Fatma M Shebl; Susan T Mayne; Nicolas Wentzensen; Mark P Purdue; Allan Hildesheim; Rashmi Sinha; Neal D Freedman Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-21 Impact factor: 4.254
Authors: Giuseppe Grosso; Agnieszka Micek; Justyna Godos; Salvatore Sciacca; Andrzej Pajak; Miguel A Martínez-González; Edward L Giovannucci; Fabio Galvano Journal: Eur J Epidemiol Date: 2016-10-03 Impact factor: 8.082
Authors: E Koloverou; D B Panagiotakos; C Pitsavos; C Chrysohoou; E N Georgousopoulou; A Laskaris; C Stefanadis Journal: Eur J Clin Nutr Date: 2015-07-01 Impact factor: 4.016
Authors: Erikka Loftfield; Marilyn C Cornelis; Neil Caporaso; Kai Yu; Rashmi Sinha; Neal Freedman Journal: JAMA Intern Med Date: 2018-08-01 Impact factor: 21.873
Authors: Dong Hang; Oana A Zeleznik; Xiaosheng He; Marta Guasch-Ferre; Xia Jiang; Jun Li; Liming Liang; A Heather Eliassen; Clary B Clish; Andrew T Chan; Zhibin Hu; Hongbing Shen; Kathryn M Wilson; Lorelei A Mucci; Qi Sun; Frank B Hu; Walter C Willett; Edward L Giovannucci; Mingyang Song Journal: Diabetes Care Date: 2020-08-11 Impact factor: 19.112
Authors: J C Dickson; A D Liese; C Lorenzo; S M Haffner; S M Watkins; S J Hamren; J K Stiles; L E Wagenknecht; A J Hanley Journal: BMC Gastroenterol Date: 2015-07-28 Impact factor: 3.067